

INTERIM FORMULARY UPDATE

The following recommendations, made at the July 18, 2014 meeting of the Executive Formulary Committee, are approved:

Product(s) **approved to be added** to the DADS/DSHS Drug Formulary based on New Drug Applications:

Generic Name	Brand Name	Dosage Form	Classification
Saliva Substitute	Various	Various	Topical Agents; Nasal, Mouth and Throat Agents

Product(s) **proposed to be deleted** from DADS/DSHS Drug Formulary:

Generic Name	Brand Name	Dosage forms to be deleted	Dosage forms still available
Procainamide	Pronestyl [®]	Capsule: 250mg, 375mg, 500mg Tablet: 250mg, 375mg, 500mg Tablet, sustained release: 250mg, 500mg, 750mg, 1000mg.	None

Product(s) **deleted** from the DADS/DSHS Drug Formulary:

Generic Name	Brand Name	Dosage forms to be deleted	Dosage forms still available
Pergolide	Permax [®]	All	None
Thyroid, Desiccated	Thyroid [®] (pork source)	Capsule: 60mg, 120mg, 180mg, 300mg	None
	Armour	Tablet: 15mg, 30mg, 60mg, 90mg, 120mg, 180mg, 240mg, 300mg	None
	Thyrolar (bovine source)	Tablet: 30mg, 60mg, 120mg	None
	Thyroid Strong	Tablet (60mg is equivalent to 90mg thyroid, USP)	None
	Thyroid, USP:	Tablet: 15mg, 30mg, 60mg, 120mg, 180, 300mg	None

Other **Recommendation(s)/addition(s)/revisions(s)** to the tables listed in the DADS/DSHS Drug Formulary

From the **Drug Formulary Sectional Review: Antiparkinson Agents Cardiovascular Agents**

- Delete prazosin from the Miscellaneous Antihypertensive section and add it to the Miscellaneous Psychotropic Agents section. The Committee recommended the addition of prazosin to the psychotropic consent list.
- Move Adenosine, dopamine, and norepinephrine/levarterenod to reserve status with the following criteria for use:
 - To be used in an ECT Suite or under the direction of an anesthesiologist.

Approved:

Ann Richards

Ann Richards, Pharm., D.BCPP
Pharmacy Services Director
San Antonio State Hospital